References
- Kozikowski A, Xia Y, Reddy R, et al. Synthesis of huperzine A and its analogues and their anticholinesterase activity. J Org Chem. 1991;56(15):4636–4645.
- Liu JP, Zhu Y, Yu C, et al. The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity. Can J Chem. 1986;64(4):837–839.
- Tun MK, Herzon SB. The pharmacology and therapeutic potential of (-)-huperzine A. J Exp Pharmacol. 2012;4:113–123.
- Jaswinder K, Rajmeet S, Gurinder S, et al. A systematic review on Huperzia serrata. Intern J Pharmacognosy Phytochemical Res. 2016;8(8):1250–1255.
- Guo B, Xu L, Wei Y, et al. [Research advances of Huperzia serrata (Thunb.) Trev]. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica. Zhongguo Zhong Yao Za Zhi. 2009;34(16):2018–2023.
- Ma X, Tan C, Zhu D, et al. A survey of potential huperzine A natural resources in China: the Huperziaceae. J Ethnopharmacology. 2006;104(1–2):54–67.
- Hao Z, Liu M, Liu Z, et al. Huperzine A for vascular dementia. Cochrane Database Syst Rev. 2009;(2):Cd007365.
- Huang P, Li B, Guo YH, et al. Efficacy and safety of huperzine A in treating patients with mild cognitive impairment: a systematic review and Meta-analysis. Zhongguo Zhong Yao za Zhi = Zhongguo Zhongyao Zazhi = China Journal of Chinese Materia Medica. 2019;44(3):582–588.
- Yang G, Wang Y, Tian J, et al. Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials. PloS One. 2013;8(9):e74916.
- Yue J, Dong BR, Lin X, et al. Huperzine A for mild cognitive impairment. Cochrane Database Syst Rev. 2012;12:CD008827.
- Dietary Supplement Health and Education Act of 1994. Public Law 103-417; 103rd Congress. [cited 2019 Nov 30]. Available from: https://ods.od.nih.gov/About/DSHEA_Wording.aspx#sec1.
- Chinese Pharmacopoeia. Pharmacopoeia of the People’s Republic of China (Chinese Edition). China Medical Science Press, Beijing, China 2015.
- U.S. Food and Drug Administration. Dietary Supplement Labeling Guide. 2005. [cited 2019 Oct 3]. Available from: https://www.fda.gov/food/dietary-supplements-guidance-documents-regulatory-information/dietary-supplement-labeling-guide.
- Stolz A, Navarro V, Hayashi PH, et al. Severe and protracted cholestasis in 44 young men taking bodybuilding supplements: assessment of genetic, clinical and chemical risk factors. Aliment Pharmacol Ther. 2019;49(9):1195–1204.
- Anderson C, Anderson D, Harre N, et al. Case study: two fatal case reports of acute yohimbine intoxication. J Anal Toxicol. 2013;37(8):611–614.
- Kearney T, Tu N, Haller C. Adverse drug events associated with yohimbine-containing products: a retrospective review of the California Poison Control System reported cases. Ann Pharmacother. 2010;44(6):1022–1029.
- Li J, Wu HM, Zhou RL, et al. Huperzine A for Alzheimer's disease. The Cochrane Database Syst Rev. 2008;(2):Cd005592.
- Alzheimer's Disease Association. Taking control: A guide for early-stage Alzheimer's disease. [cited 2019 Oct 3]. Available from: https://wwwalzorg/media/manh/documents/alzhiemer_s-taking-control-guide-(tcg)pdf.
- Mayo Clinic Fact Sheet. Huperzine A: Can it treat Alzheimer's? [cited 2019 Oct 3]. Available from: https://wwwmayoclinicorg/diseases-conditions/alzheimers-disease/expert-answers/huperzine-a/faq-20058259.
- Rafii M, Walsh S, Little J, for the Alzheimer's Disease Cooperative Study, et al. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 2011;76(16):1389–1394.
- Tucker J, Fischer T, Upjohn L, et al. Unapproved Pharmaceutical Ingredients Included in Dietary Supplements Associated With US Food and Drug Administration Warnings. JAMA Netw Open. 2018;1(6):e183337.
- Cohen PA, Travis JC, Keizers PHJ, et al. The stimulant higenamine in weight loss and sports supplements. Clin Toxicol. 2019;57(2):125–130.
- Hapke HJ, Strathmann W. Pharmacological effects of hordenine. DTW Dtsch Tierarztl Wochenschr. 1995;102(6):228–232.
- Avula B, Bae JY, Chittiboyina AG, et al. Liquid chromatography-quadrupole time of flight mass spectrometric method for targeted analysis of 111 nigrogen-based compounds in weight loss and ergogenic supplements. J Pharm Biomed Anal. 2019; 174”:305–323.
- Bereczki D, Fekete I. Vinpocetine for acute ischaemic stroke. Cochrane Database Syst Rev. 2008;(1):Cd000480.
- National Toxicology Program. Chemical information review document for vinpocetine CAS No. 42971-09-5. [cited 2019 Nov 21]. Available from: https://ntpniehsnihgov/ntp/htdocs/chem_background/exsumpdf/vinpocetine091613_508pdf. 2013.
- Ostrovskaya RU, Seredenin SB, Voronina TA. On the problem of memory-anxiety interaction: Anxiolytic effect of the memory improving dipeptide GVS -111. Animal Models in Biological Psychiatry. New York: Nova Science Publishers Inc.; 2006.
- Kazlauskas R. Advances in sports drug testing: an overview. Drug Test Analysis. 2010;2(11-12):523–525.
- FDA takes action against 17 companies for illegally selling products claiming to treat Alzheimer's disease [press release]. 2019. [cited 2019 Nov 21]. Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm631064.htm.
- Roe AL, McMillan DA, Mahony C. A tiered approach for the evaluation of the safety of botanicals used as dietary supplements: an industry strategy. Clin Pharmacol Ther. 2018;104(3):446–457.